JP2023524401A - 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾 - Google Patents

遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾 Download PDF

Info

Publication number
JP2023524401A
JP2023524401A JP2022563990A JP2022563990A JP2023524401A JP 2023524401 A JP2023524401 A JP 2023524401A JP 2022563990 A JP2022563990 A JP 2022563990A JP 2022563990 A JP2022563990 A JP 2022563990A JP 2023524401 A JP2023524401 A JP 2023524401A
Authority
JP
Japan
Prior art keywords
aav
amino acid
genetically modified
variant
capsid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524401A5 (https=
Inventor
アビシェク チャッテルジー
レイチェル イー． ケレメン
サラ ビー． エリックソン
チュアン ファム
Original Assignee
トラスティーズ オブ ボストン カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トラスティーズ オブ ボストン カレッジ filed Critical トラスティーズ オブ ボストン カレッジ
Publication of JP2023524401A publication Critical patent/JP2023524401A/ja
Publication of JP2023524401A5 publication Critical patent/JP2023524401A5/ja
Priority to JP2025267976A priority Critical patent/JP2026062759A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022563990A 2020-05-01 2021-05-03 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾 Pending JP2023524401A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025267976A JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018573P 2020-05-01 2020-05-01
US63/018,573 2020-05-01
PCT/US2021/030489 WO2021222899A1 (en) 2020-05-01 2021-05-03 Controlled modification of adeno-associated virus (aav) for enhanced gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025267976A Division JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾

Publications (2)

Publication Number Publication Date
JP2023524401A true JP2023524401A (ja) 2023-06-12
JP2023524401A5 JP2023524401A5 (https=) 2024-05-08

Family

ID=76392408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563990A Pending JP2023524401A (ja) 2020-05-01 2021-05-03 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾
JP2025267976A Pending JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025267976A Pending JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾

Country Status (9)

Country Link
US (1) US20230175013A1 (https=)
EP (1) EP4143206A1 (https=)
JP (2) JP2023524401A (https=)
KR (1) KR20230005941A (https=)
CN (1) CN115551878A (https=)
AU (1) AU2021264081A1 (https=)
CA (1) CA3177573A1 (https=)
IL (1) IL297780A (https=)
WO (1) WO2021222899A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025230000A1 (ja) * 2024-05-01 2025-11-06 Ｊｃｒファーマ株式会社 修飾されたａａｖ粒子、その製造方法、関連する医薬及びその製造

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188967A1 (en) 2024-03-06 2025-09-12 Trustees Of Boston College Precise adeno-associated virus-protein conjugates and uses thereof
WO2026037731A1 (en) 2024-08-12 2026-02-19 Coave Therapeutics Squaramide-modified viral vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297855A1 (en) * 2013-10-30 2016-10-13 Peking University Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302092B6 (cs) * 1998-02-12 2010-10-06 Immune Complex, Corporation Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek
SI1633772T1 (sl) * 2003-06-19 2016-06-30 Genzyme Corporation AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
WO2010093784A2 (en) * 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
JP6836999B2 (ja) * 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ アデノ随伴ウイルス変異体及びその使用方法
EP3813845A4 (en) * 2018-05-15 2022-10-26 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297855A1 (en) * 2013-10-30 2016-10-13 Peking University Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025230000A1 (ja) * 2024-05-01 2025-11-06 Ｊｃｒファーマ株式会社 修飾されたａａｖ粒子、その製造方法、関連する医薬及びその製造

Also Published As

Publication number Publication date
US20230175013A1 (en) 2023-06-08
JP2026062759A (ja) 2026-04-10
AU2021264081A1 (en) 2022-11-03
WO2021222899A1 (en) 2021-11-04
KR20230005941A (ko) 2023-01-10
EP4143206A1 (en) 2023-03-08
CA3177573A1 (en) 2021-11-04
IL297780A (en) 2022-12-01
CN115551878A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
US10087217B2 (en) Adeno-associated virus with site-directed mutagenesis and site-directed modification and preparation method and application thereof
CN112041451B (zh) 基于aav的基因和蛋白质递送模块化系统
JP2026062759A (ja) 遺伝子治療の増強のためのアデノ随伴ウイルス（ａａｖ）の制御された修飾
KR20200130337A (ko) Aav 키메라
CA2172139A1 (en) Endosomolytically active particles
JP7640538B2 (ja) 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
JP2025098162A (ja) 哺乳動物細胞における非天然アミノ酸の組み込みのための強化されたプラットフォーム
CN119095973A (zh) 腺相关病毒的缀合
KR20220097869A (ko) 비자연 아미노산의 부위-특이적 도입을 위한 아미노아실-tRNA 신테타제 및 세포주
CA3092451C (en) A modular system for gene and protein delivery based on aav
WO2025021771A1 (en) Methods of preparing surface modified viral capsids
Wang Role of the AAV receptor in AAV cell entry and trafficking
JP3095248B2 (ja) 核酸運搬体
Kelemen et al. Incorporation of unnatural amino acids into the capsid of adeno-associated virus
WO2025188967A1 (en) Precise adeno-associated virus-protein conjugates and uses thereof
CN121569040A (zh) 脑趋向性aav突变体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407